Companies › MeiraGTx
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Neurology, Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV2-hAQP1 AAV2-delivered aquaporin-1 gene therapy | AQP1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | Jun 2027 |
| AAV-GAD Glutamic acid decarboxylase (GAD) gene transfer via adeno-associated virus | GAD1 | Phase 1 | Parkinson's Disease | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05926765 | AAV2-hAQP1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | Oncology | Jun 2027 |
| NCT05894343 | AAV-GAD | Phase 1 | Parkinson's Disease | Neurology | Oct 2029 |
Cash of $143m on 2026-06-30; operating cash outflow about $42m a year; runway about 41 months at that burn, to Nov 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Rapa Therapeutics Ever Supreme Bio Technology Hrain Biotechnology Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.